Evidence-Based Treatment Algorithm for Obsessive-Compulsive Disorder

First-Line Treatment

The American College of Psychiatrists recommends Cognitive-Behavioral Therapy with Exposure and Response Prevention (CBT with ERP) as the psychological treatment of choice for OCD, demonstrating superior efficacy with a number needed to treat of 3 compared to 5 for SSRIs 1, 2
CBT with ERP is recommended as monotherapy for mild to moderate OCD without severe comorbid depression, and for patients who prefer non-pharmacological treatment 3
CBT with ERP consists of 10-20 sessions delivered individually, in groups, or via internet-based protocols with equivalent effectiveness 2
Between-session homework exercises are the strongest predictor of good short-term and long-term outcomes 2, 3

The American Psychiatric Association recommends optimizing SSRI dose or switching to a different SSRI when first-line treatment fails after adequate trials (8-12 weeks at maximum tolerated dose) 1, 2
Clomipramine can be considered as a second-line treatment option, which is more efficacious than SSRIs in meta-analyses but has lower tolerability 3
CBT augmentation of SSRIs shows larger effect sizes than antipsychotic augmentation, and can be added to ongoing SSRI therapy if not already implemented 1, 2
Antipsychotic augmentation, such as risperidone and aripiprazole, can be considered for treatment-resistant OCD, but with ongoing monitoring of risk-benefit ratio 4, 2

The International OCD Foundation recommends deep brain stimulation (DBS) as a third-line treatment option for very intractable cases of OCD, with approximately 30-50% of patients responding to treatment 4
DBS targets include striatal areas such as the anterior limb of the internal capsule, ventral capsule and ventral striatum, nucleus accumbens, or ventral caudate nucleus 4

Family accommodation, where family members provide reassurance or enable compulsions, can maintain the OCD cycle and undermine treatment, and psychoeducation must include family members to instruct them to compassionately decline providing reassurance while supporting the patient's ERP work 3
Prioritize mood stabilization first with mood stabilizers plus CBT, avoiding SSRIs as monotherapy due to risk of mood destabilization in patients with comorbid bipolar disorder and OCD 2

The American College of Cardiology is not mentioned, however, the guideline society is not specified, but according to the Nature Reviews Disease Primers, N-acetylcysteine (NAC) has the strongest evidence base among glutamatergic augmentation agents for treating compulsive behaviors in OCD, with three out of five randomized controlled trials demonstrating superiority to placebo in reducing OCD symptoms, and should be considered as an adjunctive treatment at doses of 2000-3000 mg/day for 12 weeks or longer 5
NAC stands out among glutamatergic medications as having the largest evidence base for augmentation in treatment-resistant OCD, with the Nature Reviews Disease Primers guidelines specifically highlighting NAC's superior evidence compared to other glutamatergic agents for compulsive behaviors 5

NAC works by modulating cortico-striato-thalamo-cortical (CSTC) circuits implicated in compulsive behaviors 5

While memantine also has demonstrated efficacy in several trials for treatment-resistant OCD, NAC has the larger evidence base and should generally be considered first among glutamatergic agents, according to the Nature Reviews Disease Primers 5
NAC is positioned as a second to third-line option, before or alongside antipsychotic augmentation, after adequate trials of SSRIs plus CBT with exposure and response prevention have been attempted 5

Three of five RCTs were positive for symptom reduction in obsessive-compulsive disorder, with NAC as an adjunctive treatment 5
Approximately 60% response rate based on positive RCTs, with marked improvement defined as >35% symptom reduction, according to the Nature Reviews Disease Primers 5